

DOTATATE

Cat. No.:	HY-106244
CAS No.:	177943-88-3
Molecular Formula:	C ₆₅ H ₉₀ N ₁₄ O ₁₉ S ₂
Molecular Weight:	1435.62
Sequence Shortening:	{D-Phe}-CY-{D-Trp}-KTCT (Disulfide bridge:Cys2-Cys7)
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	DOTATATE, a DOTA-conjugated peptide, and can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide therapy (PRRT) ^{[1][2][3][4]} .
In Vivo	¹⁷⁷ Lu-DOTATATE shows excellent antitumor effects in rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Jong M, et, al. Combination radionuclide therapy using ¹⁷⁷Lu- and ⁹⁰Y-labeled somatostatin analogs. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S.
- [2]. Gains JE, et, al. ⁶⁸Ga-DOTATATE and ¹²³I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020 Aug 10.
- [3]. Breeman WAP, et, al. Optimising conditions for radiolabelling of DOTA-peptides with ⁹⁰Y, ¹¹¹In and ¹⁷⁷Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20.
- [4]. Reubi JC, et, al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27(3):273-82.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA